Effect of Emergency Percutaneous Coronary Intervention Combined with Sacubitril and Valsartan on the Cardiac Prognosis in Patients with Acute Myocardial Infarction

References

• Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 2019 Chinese society of cardiology (CSC) guidelines for the diagnosis and management of patients with ST segment elevation myocardial infarction. Chin J Cardiol. 2019;47(10):766–783. doi:10.3760/cma.j.issn.0253-3758.2019.10.003
   Google Scholar
• Shen-Guo B. Comparison of Percutaneous Coronary Intervention (PCI) and intravenous thrombolytic therapy in patients with acute myocardial infarction. J Math Med. 2019;32(12):1762–1763.
   Google Scholar
• Cun-fang C, Jia B, Shan J, et al. Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with midrange ejection fraction. Chin J New Drugs Clin Remed. 2020;39(2):88–92.
   Google Scholar
• Cannon JA, Shen L, Jhund PS, et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(1):129. doi:10.1002/ejhf.687
   PubMed Web of Science ®Google Scholar
• Wachter R, Senni M, Senni M, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSI-TION study. Eur J Heart Fail. 2019;21(8):998–1007. doi:10.1002/ejhf.1498
   PubMed Web of Science ®Google Scholar
• Jie L, Yan Y, Hong-Yu S. Study on the effect of chest pain center construction on treatment efficiency and prognosis of acute myocardial infarction. J Clin Emerg. 2019;20(10):767–770.
   Google Scholar
• Neumann FJ, SOUSA-UVA M, Ahlsson A, et al. 2018 ESC/ EACTS guidelines on myocardial revascularization. The task force on myocardial revascularization of the European society of cardiology (ESC) and European Association for cardio-thoracic surgery (EACTS). G Ital Cardio. 2019;20(7/8S1):1S–61. doi:10.1714/3203.31801
   Web of Science ®Google Scholar
• Qi D, Shu-Hong W, Ye-zi F, et al. Risk factors of slow / no reflow in patients with acute ST-segment elevation myocardial infarction during direct percutaneous coronary intervention. Chin J Evid-Bases Cardiovasc Med. 2020;12(3):364–369.
   Google Scholar
• Li P, Ruan JW, Liu M, et al. Thrombus aspiration catheter improve the myocardial reperfusion of STEMI patients with high thrombus load during the emergency PCI operation. J Cardio-Thorac Surg. 2019;14(1):172.
   Google Scholar
• Lee JM, Rhee TM, Hahn JY, et al. Multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction with cardiogenic shock. J Am Coll Cardiol. 2018;71(8):844–856. doi:10.1016/j.jacc.2017.12.028
   PubMed Web of Science ®Google Scholar
• Nakano Y, Matoba T, Tokutome M, et al. Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation. Sci Rep. 2016;6:29601. doi:10.1038/srep29601
   PubMed Web of Science ®Google Scholar
• Qi-dong W, Mu-qiao L. Effect of sacubitril valsartan on cardiac function in patients with acute ST-segment elevation myocardial infarction of the anterior wall complicated with heart failure. Acad J Guangzhou Med Colle. 2019;47(1):92–95.
   Google Scholar
• Qing G, Guo-qing L, Qiong G, et al. Recombinant human brain natriuretic peptide sacubitril/valsartan by sequential therapy improves acute heart failure. Pract Med. 2021;37(7):919–923.
   Google Scholar
• Badae NM, Naggar AE, Sayed SE. Could cardioprotective effect of ACE2 activator “diminazene aceturate” is more potent than ACE inhibitor “Enalapril” on acute myocardial infarction in rats? Can J Physiol Pharmacol. 2019;96(8):1–12.
   Google Scholar
• Chong D, Long-Long H, Kai Z, et al. Treatment comparison between actual dose of sacubitril-valsartan and target dose of ACEI in patients with heart failure with reduced ejection fraction: a real-world cohort study. Pract Med. 2020;36(22):3084–3093.
   Google Scholar
• Wen H, Ji-huan Q, Lang H, et al. Clinical effect of sacubitril valsartan in treating heart failure patients with mid-range ejection fraction. Chin Heart J. 2020;32(2):135–139.
   Google Scholar
• Wachter R, Fonseca AF, Balas B, et al. Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21:1.
   PubMed Web of Science ®Google Scholar
• Lin-lin H, Bang-ning W, Jun F, et al. Correlation of preoperative plasma NT-proBNP level with slow / no blood flow and short-term prognosis after emergency PCI in patients with acute myocardial infarction. Guizhou Medl J. 2019;43(12):1939–1940.
   Google Scholar
• Zhi-di L. Clinical observation of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum BNP level. Chin J Primary Med Pharm. 2020;27(5):586–590.
   Google Scholar
• Jin P, Bin-yue Z, Hui-yong D, et al. Clinical analysis of Sacubitril-Valsartan in patients with clinical diastolic heart failure. Pract Med. 2021;37(11):1461–1465.
   Google Scholar
• Cohen E, Margalit I, Shochat T, et al. Gender differences in homocysteine concentrations, a population-based cross-sectional study. Nutr Metab Cardiovasc Dis. 2019;29(7):9–14. doi:10.1016/j.numecd.2018.09.003
   PubMedGoogle Scholar
• Lin L, Jin L, Chuang H, et al. Clinical value of detection of high-sensitivity C-reactive protein and cystatin C in patients with ventricular remodeling after acute myocardial infarction. Hebei Med. 2019;25(12):2045–2049.
   Google Scholar